PPARgamma is a nuclear receptor whose transcriptional activity is regulated by ligands including endogenous lipid and prostaglandin molecules and synthetic, thiazolidinedione drugs (TZDs). Published evidence from the sponsor's lab indicates that endogenous PPARgamma ligands normally dampen insulin action. In contrast, TZD ligands are potent insulin-sensitizing agents that ameliorate insulin resistance in a variety of disease states in rodents and humans. To understand the etiology of insulin resistance and its associated disease states (e.g. type 2 diabetes, obesity), it is crucial to identify and characterize genes that modulate insulin sensitivity.
The aims of this proposal are to identify ligand-specific, direct and indirect target genes regulated by PPARgamma, characterize the mechanisms by which specific gene promoters are directly PPARgamma-regulated, and screen for PPARgamma-regulated genes that affect insulin action. A large set of PPARgamma-regulated genes have been identified in our lab using DNA microarrays in preliminary studies. The ligand-specific sensitivity of these genes to direct, PPARgamma-regulation will be examined in dose response and time course experiments, coregulator recruitment and histone acetylation studies, and ligand-ligand antagonism studies. Candidate insulin-sensitizing genes, commonly regulated by insulin-sensitizing PPARgamma ligands, will be screened for their ability to mediate insulin action in 3T3-L1 adipocytes. Information regarding the genes that mediate insulin sensitivity and the mechanisms governing their PPARgamma-regulated expression will clarify how insulin action is mediated and expedite the design of improved therapies for insulin-mediated disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
5K01DK062025-03
Application #
6752758
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2002-09-15
Project End
2006-06-30
Budget Start
2004-07-01
Budget End
2006-06-30
Support Year
3
Fiscal Year
2004
Total Cost
$121,770
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Hsiao, Gene; Chapman, Justin; Ofrecio, Jachelle M et al. (2011) Multi-tissue, selective PPARýý modulation of insulin sensitivity and metabolic pathways in obese rats. Am J Physiol Endocrinol Metab 300:E164-74
Chapman, Justin; Miles, Philip D; Ofrecio, Jachelle M et al. (2010) Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS One 5:e13959
Sears, Dorothy D; Miles, Philip D; Chapman, Justin et al. (2009) 12/15-lipoxygenase is required for the early onset of high fat diet-induced adipose tissue inflammation and insulin resistance in mice. PLoS One 4:e7250
Sears, D D; Hsiao, G; Hsiao, A et al. (2009) Mechanisms of human insulin resistance and thiazolidinedione-mediated insulin sensitization. Proc Natl Acad Sci U S A 106:18745-50
Sears, Dorothy D; Hsiao, Albert; Ofrecio, Jachelle M et al. (2007) Selective modulation of promoter recruitment and transcriptional activity of PPARgamma. Biochem Biophys Res Commun 364:515-21
Miller, Yury I; Viriyakosol, Suganya; Worrall, Dorothy S et al. (2005) Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 25:1213-9
Miller, Yury I; Worrall, Dorothy S; Funk, Colin D et al. (2003) Actin polymerization in macrophages in response to oxidized LDL and apoptotic cells: role of 12/15-lipoxygenase and phosphoinositide 3-kinase. Mol Biol Cell 14:4196-206